sk&f 81297 has been researched along with Parkinson Disease, Secondary in 7 studies
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Furthermore, the inhibitory effects on striatal nerve cell firing rate by the D1 receptor agonist SKF 81297 were not different in noninnervated or reinnervated areas of the striatum compared to the control side as seen from the dose-response curves." | 1.31 | Fetal ventral mesencephalic grafts functionally reduce the dopamine D2 receptor supersensitivity in partially dopamine reinnervated host striatum. ( Andbjer, B; Fuxe, K; Kehr, J; Strömberg, I, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Flores, AJ | 1 |
| Bartlett, MJ | 1 |
| Root, BK | 1 |
| Parent, KL | 1 |
| Heien, ML | 1 |
| Porreca, F | 1 |
| Polt, R | 1 |
| Sherman, SJ | 1 |
| Falk, T | 1 |
| Kalda, A | 1 |
| Herm, L | 1 |
| Rinken, A | 1 |
| Zharkovsky, A | 1 |
| Chen, JF | 1 |
| Dupre, KB | 1 |
| Ostock, CY | 1 |
| Eskow Jaunarajs, KL | 1 |
| Button, T | 1 |
| Savage, LM | 1 |
| Wolf, W | 1 |
| Bishop, C | 1 |
| Vermeulen, RJ | 3 |
| Drukarch, B | 3 |
| Sahadat, MC | 1 |
| Goosen, C | 1 |
| Wolters, EC | 1 |
| Stoof, JC | 3 |
| Andringa, G | 2 |
| Cools, AR | 2 |
| Renier, WO | 1 |
| Strömberg, I | 1 |
| Kehr, J | 1 |
| Andbjer, B | 1 |
| Fuxe, K | 1 |
7 other studies available for sk&f 81297 and Parkinson Disease, Secondary
| Article | Year |
|---|---|
The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benzazepines; Dizocilpine Maleate; Drug Synergism; Dyskinesia, Drug-I | 2018 |
Co-administration of the partial dopamine D2 agonist terguride with L-dopa attenuates L-dopa-induced locomotor sensitization in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Benzazepines; Caffeine; Corpus Str | 2009 |
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Benzazepines; Ch | 2011 |
The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Corpus Striatum; Dopamine Agoni | 1994 |
Dopamine receptor subtypes as targets for the pharmacotherapy of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1998 |
The validity of the pretreated, unilaterally MPTP-treated monkeys as a model of Parkinson's disease: a detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF 81297.
Topics: Animals; Arm; Behavior, Animal; Benzazepines; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonia; | 1999 |
Fetal ventral mesencephalic grafts functionally reduce the dopamine D2 receptor supersensitivity in partially dopamine reinnervated host striatum.
Topics: Animals; Apomorphine; Benzazepines; Brain Tissue Transplantation; Corpus Striatum; Dopamine; Dopamin | 2000 |